CASE CCC IN THE NEWS
Cleveland Clinic Develops Clinical Screening Program for Top Genetic Cause of Colon Cancer
EurekAlert - Feb 14, 2013
Led by Charis Eng, MD, PhD, Hardis Chair and Founding Director of the Cleveland Clinic Lerner Research Institute's Genomic Medicine ...
Discovery in HIV May Solve Efficiency Problems for Gene Therapy
EurekAlert (press release)-Feb 14, 2013
Led by professor Eric Arts, PhD, the scientists discovered that the process of gene therapy..."Using lentivirus for gene transfer appears to be a safe option," said Stanton L. Gerson, MD, director of the Case Comprehensive Cancer Center ...
Lentigen Receives U.S. Orphan Drug Designation for Novel Gene Therapy for Glioblastoma Multiforme
Yahoo Finance - Feb 13, 2013
LG631-CD34 is currently being evaluated in a NIH grant-funded Phase I clinical trial at University Hospitals (UH) Case Medical Center under the leadership of Stanton Gerson, MD...and Andrew Sloan, MD...
Vaccine With Drug Payload Shows Promise Against Tumors
U.S. News & World Report - Feb 11, 2013
While the study is "by no means definitive" overall, that's good news, said Dr. Neal Meropol, chair of the division of hematology and oncology at ...
Summer Volunteers: Placements Needed
It's that time of year again where we receive requests from students inquiring about summer research positions. If you have room in your lab for a summer student, please send an email to Lyn Haselton, Cancer Center Training Program Manager. We will add your name to a list and will send you resumes if we receive them.
Case CCC Funding for Pilot/Phase I Clinical Trials
The Case CCC is encouraging investigators to submit Letters of Intent for Early Phase Clinical Research Support (EPCRS; former Protocol Specific Research Support) funding. These in-house funds are available for the conduct of early phase clinical trials of relatively short duration. Revised NCI Cancer Center Support Grant EPCRS guidelines are effective as of April 1, 2013. Studies developed jointly between UH and Cleveland Clinic with planned accrual at both institutions will be given higher priority. There are no specific deadlines for submission, and applications will be accepted until all funds are committed. Please direct questions and requests for information about the revised guidelines and funding process to Katarzyna Karelus, Clinical Research Office Administrative Director, email@example.com, 216.844.4176.
Tissue Microarray Survey
The Cancer Center is considering an initiative to build a series of Tissue Microarrays (TMAs) for member usage. We would like to assess the needs of our members so that we can start with the most feasible and useful TMAs. Please take this short survey regarding your research goals and needs.
Database Systems Development Survey
The Cancer Center is considering a more standardized and integrated database system to assist members in collection of clinical and research datasets. This new system would allow for the integration of many types of data that are commonly used in research studies, such as (but not limited to) biological samples, data from the clinical record, outcomes, pathology, survey, demographics and "omics" data results.
We recognize that we do not have optimal systems currently in place. To help us assist you in your research needs regarding your data collection and data management needs over the next 2 to 5 years, we have developed a short questionnaire.
We cannot entertain this investment without considerable use by Cancer Center members. Your responses will help us make a strategic decision on database systems development.
Reminder: Registration of Studies in Clinicaltrials.gov and Reporting of Clinical Trial Results
Section 801 of the Food and Drug Administration Amendments Act (FDAAA 801) requires Responsible Parties to register and submit summary results of clinical trials with Clinicaltrials.gov. Clinical trial results registration became effective as of September 2008. The FDA is currently empowered to enforce the reporting requirements, as well as financial penalties on non-compliant investigators and institutions.
Clinical trial and result registration is centralized within the Case CCC, and April Firstencel, Case CCC Registration Coordinator, has been working with investigators, study staff and statisticians to ensure the Case CCC complies with federal requirements. This announcement serves as a reminder about our on-going efforts and the need for everybody's assistance and collaboration to meet these obligations. Please direct questions to April Firstencel, Case CCC Registration Coordinator for Clinicaltrials.gov, 216.286.2294, firstname.lastname@example.org.
The American Society of Hematology (ASH) has partnered with the Harold Amos Medical Faculty Development Program (AMFDP) of the Robert Wood Johnson Foundation to increase the number of scholars from historically disadvantaged backgrounds receiving academic and research appointments in the field of hematology. The AMFDP offers four-year postdoctoral research awards to historically disadvantaged physicians who are committed to developing careers in academic medicine and to serving as role models for students and faculty of similar backgrounds. The program defines "historically disadvantaged" individuals as those who face challenges because of their race, ethnicity, socioeconomic status, or other similar factors.
Deadline: March 14
Computational Genomic Epidemiology of Cancer Postdoctoral Training Program
The Case CCC invites applications to its 2-3 year NCI-funded Computational Genomic Epidemiology of Cancer Postdoctoral Training Program. The program combines a mentored cancer research project designed by the fellow in collaboration with their mentors with a specialized curriculum of formal didactic training and individualized longitudinal curriculum.
This program is designed to prepare trainees for careers as independent investigators engaged in research at the intersection of cancer research, genetics, epidemiology, biostatistics and computer science. Cancer researchers obtaining training will have the skills vital to decipher the complex pathways comprising genetic and environmental risk factors for disease, and will ultimately be able to provide clinicians and their patients with valuable information for the prevention and treatment of cancer.
Candidates with an MD, PhD, or MD/PhD degree, strong quantitative skills, and an interest in a career in genetics research are encouraged to apply.
MARK YOUR CALENDARS
Research Best Practices Day 2013
Registration is now open for Research Best Practices Day 2013, Friday, March 1. This annual event is open to the entire research community. Each year, several topics are presented by our local experts as part of CWRU's ongoing training in the Responsible Conduct of Research. Faculty, staff and students are encouraged to attend one or more of the sessions that are applicable to their research.
Planned topics include:
- Integrity in Research and Authorship
- Understanding Health Literacy and its Impact on Informed Consent
- Maximizing the Features in UHCare to Manage your Research Participants
- Understanding Stem Cells and the new Human Stem Cell Research Oversight Committee
- Laboratory Safety: Where we were- Where we are- Where we are going
Breast Cancer Program in Development Annual Retreat
Drs. William Schiemann and Lyndsay Harris, Co-Leaders of the Breast Cancer Program in Development, invite you to attend the program Annual Retreat on Monday, March 11from 9 am-3 pm in the Dively Building on CWRU campus. The agenda and program information will be available soon.
A melanoma mini-symposium is scheduled from 3-7 pm on Monday, March 11 in the Wolstein Research Building Auditorium. The purpose of this symposium is to provide a forum for physician scientists and biomedical researchers to foster communication and develop new collaborations on melanoma research. Please watch the newsletter for updates.
Annual Cancer Center Retreat
The Annual Cancer Center Scientific Retreat will commence the evening of Thursday, July 11 and continue through Friday, July 12. Location and agenda are still be finalized. Details will be posted in the newsletter in the coming months.